Effects of Lifestyle Modification on Vestibular Migraine (LMVM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03979677|
Recruitment Status : Enrolling by invitation
First Posted : June 7, 2019
Last Update Posted : October 3, 2019
|Condition or disease||Intervention/treatment||Phase|
|Vestibular Migraine||Behavioral: Lifestyle Modifications||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Eligible participants will receive information on food/beverage triggers to avoid, restful sleep tips, simple exercise tips, and eating regularly at the same time. Participants will return after 60 days and both pre- and post-intervention measures will be obtained.|
|Masking:||None (Open Label)|
|Official Title:||Effects of Lifestyle Modification on Vestibular Migraine|
|Actual Study Start Date :||October 1, 2019|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||September 2020|
- Behavioral: Lifestyle Modifications
Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
- Headache Disability Inventory (HDI) [ Time Frame: Change in HDI total score will be determined 60-days post intervention. ]This measure assesses disease-specific (headache) health-related quality of life using a 0 - 100 scale with 0 indicative of no impact and 100 indicative of severe maximum impact. We will assess change in HDI score by comparing baseline performance to performance 60-days after intervention.
- Dizziness Handicap Inventory (DHI) [ Time Frame: Change in DHI total score will be determined 60-days post intervention. ]This measure assesses disease-specific (dizziness) health-related quality of life using a 0 - 100 scale with 0 indicative of no impact and 100 indicative of severe maximum impact.We will assess change in DHI score by comparing baseline performance to performance 60-days post-intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03979677
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|